SEARCH BY SPECIALTY
Medical Devices
Diagnostics/Labs/Biomarkers
Life Science Tools
Healthcare IT/Disease Mgmt./Telemedicine
Animal Health/Food Safety/Dental
Final LCDs from MACS Lead To Questions on Coverage for Certain MIGS Procedures for Glaucoma TreatmentHologic Reports Solid 3Q23; Mammography Backlog Driving Strong Capital Equipment SalesSBRT Data Presented at ASTRO Shows High Efficacy in Localized Kidney Cancer; Could Become First Line Treatment if it Demonstrates Superiority Versus SurgeryOwlet Receives FDA Approval For Non-Prescription Dream Sock Significantly Expanding MarketNeuronetics Announces Positive Payer Coverage Changes for NeuroStar Depression Treatment Technology Eliminating Barriers to AdoptionEnovis Reports Strong 3Q23 and Raises Full Year Outlook Based Upon Strong Hip/Knee Growth; Expects to Drive Synergies Accelerate Growth With LimaCorporate DealGE Healthcare and Masimo Partner to Add Oxygen Saturation Measurement to the Portrait Mobile Wearable Monitoring Technology for HospitalsNew AABB Guidelines Recommend More Restrictive Guidelines on Red Blood Cell TransfusionThe Robots are Coming; Johnson & Johnson Plans to Start Surgical Trials on OTTAVA in 2024Zimmer Sees Similar Trend Line to Peers With Elective Procedures Slowing From Early 2023; New CEO Focused on InnovationSI-BONE Reports Strong Growth in 3Q23 Driven by Increased Physician Adoption and Procedure ExpansionEmpatica Receives FDA Approval for Two New Biomarkers on Wearable to Support Clinical ResearchMedicare Creates New $15 Billion Market for Previously Non-Reimbursed Exoskeleton Technologies; Microcap Companies Ekso Bionics and ReWalk Robotics Could Be the Biggest BeneficiariesCerus Reports Solid 3Q23 With Meaningful Progress Towards Cash Flow Breakeven; Pending Catalysts With IFC and Red Cell Technology Provide Exciting 2024 Set-UpEndologix Shares Pooled Analysis at VIVA Showing Novel DETOUR System Results in Positive Outcomes for Severe PAD Patients With Less-Invasive TechniqueCooperCompanies Announces Streamlined Acquisition of Cook Medical Reproductive Health Assets Following FTC Intervention; Despite Smaller Scale Deal to Be Highly Accretive in 2024Gynesonics Raises $67.2 Million to Further Commercialize Innovative Uterine Fibroid Device; Follows Rash of Positive Coverage Decisions for the TechnologyInspireMD Shows Positive Data at VIVA with CGuard Carotid Stent System Demonstrating Low Rate of DSMI at 30 Days Compared to Previous StudiesBeyond Air Study Using UNO Therapy in First Patients Shows Immunostimulatory Response and Low Side Effects; Warrants Further Investigation/DataSmith + Nephew Focuses on Robotic Tool Expansion in Orthopedics/Trauma; Notes Some Elective Procedure Slowing Following the Post COVID-19 Catch UpHaemonetics Beats in the Quarter; Plasma Catchup from Pandemic and Strong Hospital Growth Continue to Drive ResultsInsulet Delivers Strong 3Q23 Based Upon Omnipod 5 Success; Product Cycle Momentum Shows No Signs of Slowing With Provider Adds, International Launch, and Type 2 Diabetes Expansion Primed for 2024Increased Barostim Reimbursement in the HOPPS Causes CVRx Stock to RallyBaxter Announces Largely In-Line 3Q22; Streamlining Portfolio to Focus on Growth With Divestiture of BioPharma Solutions and Planned Spin-Off of Kidney CareAtriCure Reports Solid Growth in 3Q23 on the Heels of New Technology Offerings for Atrial FibrillationStryker Management Very Bullish on Procedures and Capital Purchases Heading into FY24; Likely Right in Short-Term, but Broader Industry Trends Support CautionWhat Stryker and Smith & Nephew Implant Growth Can Tell Us About Elective Procedure Trends; Consistent With Earlier HCA DataTandem Diabetes Care Disappoints in 3Q23 as it Pivots to Mobi and New Offerings in 2024Nevro Corp. Beats Outlook and Raises Forecast but Faces Expanding Competition in High Growth Diabetic Neuropathy IndicationMcKesson Beats in 3Q23, GLP-1 Drives Increased Pharma Segment Revenue and Increased Prescription Technology Solutions Due to Prior Authorization Service DemandMacro Headwinds to Elective Procedures and Declining Profitability Weigh on STAAR in 3Q23Glaukos Reports Solild 3Q23 but Commentary on Physician Behavior Due to Draft MIGS LCDs Weighs on StockInari Medical Reports Solid 3Q23 and Announces Complementary LimFlow Acquisition, but Investors Worry About Dilution and Distraction from Core MarketZimVie’s 3Q23 Better than Tepid Expectations, but Elective Procedure Headwinds in Dental Likely to Worsen and U.S. Spine Competition Unlikely to AbatePenumbra Presents Interim Data From STRIKE-PE Study at VIVA Showing the Indigo Aspiration System Led to Positive Outcomes for Pulmonary Embolism PatientsXēnix Medical Receives FDA Clearance for Innovative SOLACE Sacroiliac Fixation System Using Proprietary NANOACTIV Surface TechnologyYourBio’s TAP Micro Receives CE Marking Joining Tasso+ As Cleared Technologies for Self Blood Collection; Cost and Volume Challenges Remain for Broadscale AdoptionWhat Hospital Capital Equipment Challenges? GE Healthcare Maintains Full Year Growth OutlookMIMEDX Reports Strong 3Q23; With Skin Substitute LCDs in Rear View and EPIEFFECT Launch Company Well Positioned in Fourth QuarterPulmonx Corporation Reports Strong 3Q23 and Increases Full Year Outlook With Japan Launch and AeriSeal Study PendingMovano Health’s Prototype Chip for Evie Ring Achieves FDA-Recognized Accuracy in Blood Pressure Monitoring StudySurmodics Launches New Preside™ Medical Device Coating TechnologyZynex Announces Strategic Alternative Process Aimed at Driving Shareholder ValueNew Study from Implicity Demonstrates The Ability of New Proprietary Algorithm to Reduce Alert Burden During Patient Monitoring for Atrial FibrillationZynex Appears Poised for Momentum Following Sales Force Expansion and New Product LaunchesNovocure Reports Slight 3Q23 Revenue Miss; Focus on Regulatory Submissions Following Successful LUNAR TrialResMed Delivers In-Line 3Q23; Highlights Opportunities in Digital Solutions and New Markets for Forward GrowthEkso Bionics Shows Solid Progress in 3Q23; New CMS Reimbursement Change Could be Game Changer in 2024Merit Reports Strong 3Q23 and Raises Full Year Outlook; Notes CEO Succession Plan Likely to be Announced by Year EndApple Facing Potential Import Ban for Apple Watch Based Upon IP Challenges to Health Features From AliveCor and MasimoExactech Receives Approval for New 3D-Printed Tibial Implants for Small But Fast Growing Ankle Arthroplasty MarketEdwards Lifesciences’ TRISCEND II and CLASP IID Trials at TCT Enhance Company’s Position in Transcatheter Heart Valve Regurgitation and Set the Stage for EVOQUE approval in the U.S.Dexcom Follows Abbott’s Footsteps With Exceptionally Strong 3Q23 in CGM; Medicare Expansion in Type 2 Diabetes and G7 Seem Like Early Innings of Substantial Product CycleTissue Products Recall and Facility Closure Weigh on Integra LifeSciences 3Q23 Results; Expected to Be Resolved in Mid-2024Outsource Device Manufacturer Integer Holdings Corporation Reports Strong 3Q23 and Guide; Positive Leading Indicator for Industry Cardiology and Neuromodulation MarketsBoston Scientific Reports Solid 3Q23 on Strong Cardiology Revenue; New Approvals, Acquisitions, and Data Sets Position the Company for Solid Growth AheadSurgical Products Provider CONMED Delivers Solid Performance Despite Allograft Supply DisruptionInspira Technologies Receives Key Priming Patent Supporting the INSPIRA ART500 Respiratory Support DeviceEdwards Lifesciences Reports In-Line 3Q23 But Guides Below Street for 4Q23 Following Strong Data Showing at TCTAbbott’s Espirit BTK System Outperforms Angioplasty in PAD Patients With Chronic Limb-Threatening IschemiaPositive Data for Boston Scientific’s Drug Coated Balloon Presented at TCT Could Support FDA Approval for In-Stent RestenosisAbbott Presents Positive New Data at TCT on Transcatheter Devices for Tricuspid and Mitral Valve RegurgitationFresenius Medical Care Recalls Hemodialysis Machines Due to Potential Exposure to Toxic CompoundsXtant Medical Buys Production Operations for nanOss Products from RTI Surgical Following Product AcquisitionMedtronic Evolut Trial Combined With Partner 3 Data May Be Nail in Coffin for Surgical Aortic Valves; Data Shows Lower Mortality With TAVRPartner 3 Study Showing Long-Term Safety Profile of Transcatheter Aortic Valves Could Lead to Even Further Adoption Over SurgeryGlobus Medical Presents Data From Long-Term Nuvasive Simplify Disc Study Demonstrating Superiority to Anterior Cervical Discectomy Fusion ProceduresBoston Scientific Reports Results From Electronic Health Record Study Showing EKOS Has Lower Adverse Event Rate Compared to Inari’s FlowTriever SystemHCA Earnings Shows Some Softening in Surgical Volumes From Start of YearABK Biomedical Commences Pivotal Study in Hepatocelluar Cancer with First Patient Treated Using Microsphere TechnologyAllergan Aesthetics Reports Positive Phase 3 Trial Results for New Fast Acting Neurotoxin for Face WrinklesButterfly Network Signs Ultrasound Chip Deal With Forest Neurotech to Support Brain Measurement/Modulation Implantable DeviceElekta to Acquire Xoft, a Subsidiary of iCAD, Inc.; Allows iCAD to Focus on Core Imaging Software BusinessMedtronic’s New Aurora EV-ICD Receives FDA Approval; Real World Performance Study Hopes to Show Lower Rates of Venous ComplicationsWearable Ring Maker ŌURA Announces Canadian Retail Launch in Partnership with Best BuyInsulet Corporation Achieves FDA Clearance for Omnipod 5 App for iPhoneCARMAT Reports Seven Aeson Implants Completed in EFICAS Clinical Trial for Its Total Artificial Heart Following Emergency FinancingOlympus Launches Next Generation Endoscopy SystemOrthoPediatrics Launches Pediatric Nailing Platform for Tibial FracturesIntuitive Surgical’s 3Q23 Shows Some Cracks in Capital Equipment Outlook; Procedure Growth Outlook Shows Signs of SofteningProtembis Gets FDA Approval for Cerebral Protection Device IDE; Study Design Could Show Superiority to Boston Scientific’s Sentinel DeviceGE HealthCare and Novo Nordisk Join Forces to Advance Peripheral Focused Ultrasound Treatment for Diabetes Care Edwards Life Sciences Announces CE Mark of First Transcatheter Tricuspid Valve; TRISCEND II Data Expected in June 2024 and U.S. Approval by End of 2024Apollo Neuro Launches First Wearable With Subscription Service to Address Sleep Disturbance and Reduce StressAVITA Pre-Announces Accelerating Growth in 3Q23 and Secures $90M Debt Facility Following Recent Expanded Indications for RECELL and RECELL GO Filing DelayNeuroPace Unveils RNS System Enhancements to Improve Care for Epilepsy PatientsAbbott Reports Strong Third-Quarter 2023 Results With Medical Device Sales up 15% Organically, Diagnostics up 6% Excluding COVID-19Henry Schein Completes Acquisition of Shield Medical Expanding Home Care OfferingSight Sciences Announces Strategic Cost Measures as it Awaits Final LCDs on MIGS TechnologyJNJ Reports Strong 3Q23 Results But Global Med-Tech Sales Deaccelerate; Read Throughs for Other CompaniesFisher & Paykel Healthcare Launch New F&P Solo Mask for Sleep ApneaAlphatec Showcases New Technology Offerings at NASS MeetingJohnson & Johnson Receives FDA Approval for New Foot/Ankle Plating SystemFDA Approves Establishment Labs Tissue Expander Technology for Mastectomy PatientsHenry Schein Cybersecurity Incident Disrupts Business Operations; Emblematic of Increased Risks Around Data SecurityData from Neuronetic’s NeuroStar Outcomes Registry Shows Significant Improvements in Remission/Response for Patients That Complete Full Therapy CourseNovocure Presents Data on Patient Tolerability/Quality of Life Data for NSCLC at ESMO from LUNAR TrialGE Healthcare Announces FDA Approval for Allia IGS Pulse for Cardiac Imaging ProceduresBaxter Launches New Software Application Allowing the Capture of Eye Images on a Smart Phone During Opthalmoscope ProceduresAlphatec Holdings Preliminary 3Q23 Revenue; Strong Beat Driven by Continued Adoption of Lateral Access Techniques Leads to Full-Year Guidance RaiseCOSMOS Study Demonstrates Ability of GE HealthCare’s Portrait Mobile Continuous Monitoring Solutions to Reduce Alarm Fatigue in Ward EnvironmentsSight Sciences Announces Results in SAHARA Clinical Trial Comparing TearCare vs. Standard of Care Restasis for Dry Eye DiseaseFDA Approves New Oxygenation Parameter for Masimo Pulse Oximetry PlatformMedacta Study in Shoulder Arthroplasty Further Demonstrates the Potential of Augmented Reality in OrthopedicsEstablishment Labs Presents Clinical Data On Mia Femtech, Minimally Invasive Breast Augmentation Technology; Launches New RFID SensorTough Few Months for Dialysis Company Outset Following FDA Warning Letter, Novo Nordisk GLP-1 Data, and Now Pre-Released Revenue MissGetinge Acquires Healthmark Industries Strengthening Global Position in Sterile Reprocessing MarketDaVita Releases Statement Following Stock Sell-Off on Novo Nordisk’s GLP-1 Study AnnouncementGE HealthCare Signs $44 Million Contract with BARDA to Develop AI-Enhanced POCUS Technology for Mass Casualty EventsOrthofix Medical Inc. Launches OsteoCove™ Synthetic Bone GraftBraun Launches New Introcan Safety® 2 IV Catheter to Prevent Needlestick Injuries and Blood ExposureBoston Scientific’s Neuromodulation System Receive FDA Approval for Treating Diabetic Peripheral Neuropathy; Joins Nevro, Medtronic, and Abbott in Increasingly Crowded MarketPulmonx Announces CFO Transition; Pre-Releases Above Consensus Revenue for 3Q23Masimo Gets CE Mark for New Hemodynamic Monitoring Module; Facilitates Access to Real Time Data on a Single DisplayOrthoPediatrics Launches New Functional Brace for Pediatric Femur Fracture; Data Shows Cost Benefits, Ability to Prevent General AnesthesiaGE Healthcare and SOFIE Biosciences Partner on FAP Radiopharmaceuticals Shown to Be Highly Prognostic in Cancer StudiesAllurion Completes AUDACITY Trial Enrollment for Highly Non-Invasive Weight Loss BalloonSilk Road Medical Pre-Announces Significant Revenue Miss; CEO RetirementTeleflex Completes the Acquisition of Acquisition of Palette Life SciencesFDA Issues Warning Letter to JNJ Subsidiary Abiomed Citing Issues with Impella Heart PumpAdvaMed Announces New Digital Health Tech DivisionEndotronix Announces New IDE for Class II Heart Failure Patients and Positive Early Data in PROACTIVE-HF Study for Class III PatientsHologic Partners With AAGL and Inovus to Provide Training Solutions to New OB-GYNsAlcon Introduces TOTAL30 Multifocal Contact Lenses to Address PresbyopiaHaemonetics Corporation to Acquire OpSens, Inc., Signals Further Move into Interventional CardiologyButterfly Network Introduces New Education Support ToolsBest Buy to Sell Dexcom G7 CGM System OnlineMindray Launches New Lightweight Wireless Ultrasound at ACEPMulticenter Study Using Sonex Health Technology Cites Benefits of Ultrasound-Guided Carpal Tunnel ReleaseGE Healthcare Integrates Caption Guidance Heart Failure AI Technology Into Ultrasound SolutionsGE Healthcare and University Hospitals Sign 10-Year Strategic PartnershipFresenius Kabi Receives Warning Letter from FDA on Fenwal Blood ProductsNext-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in CanadaAccuray’s Tomo® C Radiation Treatment Delivery System Approved by China’s NMPAAirLife Completes Acquisition of Avanos Medical’s Respiratory Health BusinessVapotherm Study Utilizes Computational Fluid Dynamics to Demonstrate High Velocity Therapy Leads to Better Clearance of CO2 from the AirwayButterfly Network and Razom Partner to Expand Access to Butterly iQ+ Ultrasound Technology in UkraineNanox Partners with Varex Imaging on New Manufacturing and Supply AgreementBiotricity Announces Key Patent Filing for Biotres Electrocardiogram (ECG) Wearable DeviceSight Sciences Announces Significant Head-to-Head Study on MIGS Technologies for Glaucoma PatientsAvita Medical Announces FDA Request for Additional Information on RECELL GO; Timeline for Approval Moves To Mid-2024Anumana Receives FDA 510k Approval for New AI Powered Heart Failure Diagnosis TechnologyCordis Completes Acquisition of MedAlliance in Deal Worth up to $1.135 Billion; SELUTION DeNovo Trial Could Have Big Implications for PCI MarketFollowing Lobbying by Radiologist Societies, CMS Allows for Billing of Multiple Cardiac MRI ProceduresDexcom Presents Long-Term Data from the COMISAIR Study at EASD Demonstrating Positive Outcomes for Diabetes Patients Using CGMAccuray Introduces Cenos™ Online Adaptive Therapy Option at ASTRO 2023Carlyle Group Rumored To Be in Negotiations to Buy Medtronic’s Patient Monitoring and Respiratory Business UnitsSiemens Healthineers Unveil New 3-D Mammography System with High-Speed Imaging TechnologyOrganogenesis Applauds Decision to Withdraw Medicare Local Coverage Determinations; Decision Eliminates Reimbursement Uncertainty for Company’s Wound Care ProductsNyxoah Partners with ResMed Germany to Advance Obstructive Sleep Apnea (OSA) Awareness and TherapyNanox.AI’s HealthCCSng Reveals Hidden Cardiovascular Risks in Routine CT ScansGalen Robotics Receives First FDA Approval for Robotic ENT Surgical Robot; Announces Series B Funding RoundGN Hearing and Beltone Announce Launches of Next Generation Hearing Aids4WEB Medical Expands Orthopedic Implant Portfolio with New FDA Approval; Moves Closer to Comprehensive Cervical SolutionBeacon Receives FDA Approval for Dreem 3S; Facilitates Collection of High Quality Sleep Data in the Home SettingBoston Scientific To Acquire Relievant Medsystems for $850 Million; Gains Access to Lower Back Pain TechnologyCardinal Health Launches Kangaroo OMNI™ Enteral Feeding PumpDexcom Canada and RxFood Partner to Improve Diabetes Management; RxFood App Shown To Improve Diabetes Outcomes in Clinical StudiesExo Unveils New Handheld Ultrasound Device for Point-of-Care ImagingiRhythm Unveils Next Generation Zio Monitor and Long-Term Continuous Monitoring ServiceFDA Issues Final Guidance Document on Cybersecurity Requirements for Premarket Device SubmissionsChanges for Exoskeleton Reimbursement Under Home Health Prospective Payment System Could Expand Access to TechnologiesSenseonics Completes 365-Day ENHANCE Pivotal Clinical Study, Moves Closer to One-Year Eversense Implantable Sensor ApprovalCardiosense Begins Enrollment in Nationwide Heart Failure StudyNICE Conditionally Recommends AliveCor’s KardiaMobile for Measuring Cardiac QT Intervals in Adults Taking Antipsychotic MedicationMiMedx Group Launches EPIEFFECT for Hard-to-Heal WoundsFDA Approval for BACKBEAT Study A Major Potential Win for Orchestra BioMed and Medtronic in U.S. Pacemaker MarketZimVie Receives Approval For Hybrid CDA and ACDF Study Using Mobi-C Cervical Disk ProsthesisEnovis to Acquire Global Orthopedic Company LimaCorporateProfound Medical Receives 510(k) Clearance for Thermal Boost AI Module for Use With TULSA PRO Prostate Cancer Ablation TechnologyFDA’s CDRH Division Releases Draft Strategic Plan on International Regulatory Harmonization to Lower Redundancy and Reduce Burden on Device ManufacturersAvita Medical Wins Best Product Award for Second Straight Year at American Association for the Surgery of Trauma Meeting with RECELL Spray-On Skin CellsCARMAT Reports its First Half 2023 Results and Provides a Strategic Update on Fully Artificial Heart ProgressVapotherm Study Demonstrates Better Outcomes for Pediatric Asthma Patients Treated with High-Velocity TherapyMedtronic Receives CE Mark For New Simplera Continuous Glucose Monitoring SystemInsightec Receives Humana Coverage for Focused Ultrasound Treatment in Essential TremorNew State Biomarker Legislation Advocated for by the Cancer Action Network Could Be a Game Changer for Expanding Commercial and Medicaid Access for Advanced DiagnosticsKaiser Strike Could Have Significant Impact on Patient Care; Sign of Growing Frustration Among Healthcare Workers on Labor Conditions:Neuralink Gets FDA Approval For First In-Human Use of Brain ImplantsChanges in European In-Vitro Diagnostic Device Regulation Will Begin to Impact IVD Manufacturers; New Regulation Structure Will Increase Cost and Evidence Burden to Enter MarketInternet Trend Searches Show Some Signs of Cosmetic/Elective Procedure Softening; Is it the Canary in the Coal Mine for a Softening Healthcare Consumer?UNH Prior Authorization Changes To Date Unlikely To Significantly Impact Genetic Labs or Imaging Centers; Despite Lobbying Against Burdensome Barriers to Care, to Date There Has Been Minimal Impact$8 Billion Electrophysiology Market Poised for Potential Shake Up as PFA Technologies Move to the Forefront
QIAGEN Launches New Digital PCR Kits and Software Upgrades for QIAcuity SystemExagen Inc. and Johns Hopkins University Partner to Develop Biomarkers Tests Lupus Nephritis ManagementAdaptive Biotechnologies To Conduct Strategic Review Focused on Shareholder Value Following Disappointing 3Q23Hologic Reports Solid 3Q23; Mammography Backlog Driving Strong Capital Equipment SalesStrong 3Q23 for Natera; Lots of Momentum with MRD, Potential for Medicare Renasight Coverage, and Improving ReimbursementInvitae’s 3Q23 Results Drive Further Concern About Long-Term Viability as Cash Burn Goes Wrong Direction and Revenues DeclineCOMBINEDBrain Launches WGS Study for Children With Neurodevelopmental Disorders; Broad Institute Will Perform Sequencing Using Fabric Genomics Interpretation Software23andMe Misses in 2Q24 and Losses Widen; Given Cash Concerns, Management Increasingly Focused on Margins with Price Increases, Headcount Reductions, and Planned Lower Ad SpendingMedicare Recommends Crosswalking 2nd Generation OvaWatch Test from Aspira Labs to Original Ova1 RateOraSure Beats Expectations in 3Q23; Investors Focus on Core Growth and Post InteliSwab Growth DriversAdaptive Announces Multi-Year Partnership With BeiGene to Assess MRD With clonoSEQ in Blood Cancer TrialsNatera’s Signatera Test to Be Used in European Breast Cancer Study Comparing Elacestrant to Standard Endocrine Therapy; Will Assess Whether Early Intervention Using Signatera Improves Patient OutcomesHelix Announces Another Major Population Genomics Partnership With Cone HealthNeogenomics Delivers Strong 3Q23 With Profitable Growth; RaDaR MRD Test Currently Undergoing Three Coverage Evaluations from MolDxInvitae Announces Sensitivity and Workflow Enhancements to its MRD TestClinical Volume Growth Slows Sequentially in 3Q23 for Guardant Health; Next Generation Colon Test Data Could Be Interesting if Validated in Large Study CohortMyriad Shows Significant Progress With Evident Share Gains in 3Q23; Reimbursement Changes Could Put Company on Course Back to Profitability When Combined With Expense Control23andMe Makes Pivot to Exome Sequencing With New Offering; Cost Changes in WGS Could Provide a Renaissance for the Company’s Business Model Over TimeCastle Bioscience Delivers Strong Volume Growth in 3Q23 and Makes Major Progress on ProfitabilityAbbott Joins Crowded HPV Field With FDA Approval of High-Throughput Molecular TestNatera’s Landmark RenaCARE Study Demonstrates the Ability of Genetic Testing to Dramatically Alter Patient Management in Chronic Kidney Disease; Could Establish Foundation for New Major Genetic Testing MarketQuidelOrtho Outperforms on Respiratory Revenue; Profitability Progress a Positive Despite COVID-19 HeadwindsExact Sciences Delivers a Strong 3Q23; Signs that Test Acquisition Costs are Declining and Discussion on Pricing Increase for 2nd Generation Cologuard Could Bode Well for Future ProfitabilityIQVIA Lowers 2023 Outlook and Provides Preliminary Guide for 2024 Calling for Mid-Single-Digit GrowthAgendia’s MammaPrint Test Will be Used to Risk Stratify Patients for NCI Neoadjuvant Immunotherapy Breast Cancer TrialGuardant Health Tests to Become Available on OncoEMR Platform From Flatiron Health Used by 2,000 Oncologists23andMe Unveils Health Action Plan Digital Tool; Provides Added Customer Feature and Increases Information in Proprietary Genomic DatabaseQIAGEN Weathers Macro Storm Better Than Most; QuantiFERON TB Driving Strong Diagnostic GrowthGeneDx Makes Cash Burn Progress in 3Q23 With Goal of Profitability by 2025, However, 4Q Guidance Implies Step BackwardsRevvity Faces Biopharma Challenges, COVID-19 Headwinds in 3Q23Digital Pathology Solutions Provider Paige Receives FDA Grants Breakthrough Device Designation to Lymph Node Detection Software in Breast Cancer23andMe and GSK Extend Drug Development Collaboration for Five YearsFoundation Medicine Joins NCI’s ComboMATCH Initiative to Explore New Combination Therapies for CancerLabcorp Sees Strong Organic Growth From Hospital Outsourcing Deals Overcoming COVID-19 HeadwindsPersonalis Announced Early Access Launch of NeXT Personal Dx MRD Test With Focus on Lung Cancer, Breast Cancer, and Immunotherapy ResponseQIAGEN and Myriad Announce CDx Collaboration Focused on Kitting Advanced DiagnosticsC2N Diagnostics Licenses and Introduces Novel Fluid Biomarker for Alzheimer’s DiseaseICON Follows in Medpace Holdings Footsteps With Strong Booking Trends; Supports Continued Strength in Pharma ResearchAspira Women’s Health Study Shows Combining miRNA and Protein Biomarkers Improves Diagnostic Accuracy of Ovarian Cancer TestMetabolon Partners With Genomics England to Provide Metabolomic Data on 7,000 Patients From 100,000 Genomes Project to Find Rare Disease BiomarkersMindray Launches Two New Cardiac Biomarker Tests for Myocardial Infarction and Heart FailureBostonGene Partners With Exigent Research on Clinical Utility Study for the Tumor Portrait TestMeMed Gets BARDA Contract for Novel Test to Differentiate Bacterial and Viral InfectionsInvitae Releases Study Highlighting Unknown Variant Rates in Large Genetic PanelsProstatype Interim Analysis Demonstrates Ability to Alter Patient Management and Predict Disease ProgressionCaris Signs Research Collaboration with mRNA Leader Moderna, Now Has Over 70 Biopharma PartnershipsQuanterix Enhances Alzheimer’s Offering With License to Johnson & Johnson’s p-Tau 217 AntibodiesQuest Reports Continued Strong Core Requisition Growth in 3Q23 and Solidifies Payer Contracts; LDT Regulation and PAMA Reform Remain UncertaintiesUSC Researchers Develop New Accurate Blood Test for Assessing Ovarian Cancer in Patients With Adnexal MassesDanaher 3Q23 Results Show Continued Headwinds From Bioprocessing, China, and COVID-19; Management Believes Inventory Draw Downs Will Lead to Improved Trends in 2024Neogenomics Launches Comprehensive Genomic Profiling Test for Hematomalignancies; Could Be a Strong Compliment to Existing Anatomic Pathology FranchiseMedpace Holdings, Inc. Posts Strong Q3 2023 Results and Guides Above Street for 2024; Strong Read-Through on Biopharma InvestmentData from GALAXY Study Shows Ability of Natera to Predict Outcomes and Benefit of Adjuvant Chemotherapy in Resectable Colorectal CancerPersonalis Data from TRACERx for MRD Test Appears on Par With Market Leader NateraGenoscopy Data Good, But Tough Hill to Climb Commercially Given Next Generation ColoGuard Test is More AccurateBLUE-C Trial Will Make It Even More Challenging for Imitators; Extends Exact Sciences’ Lead in Non-Invasive Colorectal Cancer DetectionFoundation Medicine Agrees to Tech Transfer with Sequanta Technologies to Support Clinical Trials for Oncology Medicines in ChinaUNH Arbitration Rulings on Unpaid Claims Could Have Significant Ramifications for Insurance Companies and Service ProvidersFoundation Medicine Announces Positive Data from CUPISCO Study in Difficult to Treat CUP Patients Will be Presented at ESMOThermo Fisher Scientific and Boehringer Ingelheim Partner to Advance Precision Cancer TherapiesMicroba Life Sciences Acquires Invivo in Deal Valued at up to A$21.5 Million; Strengthens Position in Microbiome Testing MarketPhenomix’s MyPhenome Hungry Brain Test Shows Ability to Predict Response to Weight Loss Drug QsymiaVolitionRx’s Nu.Q® NETs Test Shows Promise in Study as Sepsis Severity BiomarkerAncestry Launches Genetic Traits Feature Allowing Customers to Determine 43 Inherited Parental CharacteristicsNew CRISPR Diagnostic Company VedaBio Announces $40 Million Funding & Platform Launch; Unclear Whether Technology Uses Existing Intellectual PropertySOPHiA GENETICS Partners with Memorial Sloan Kettering and AstraZeneca To Broaden Access to Advanced Cancer TestsTelo Genomics Announces Launch of Smoldering Multiple Myeloma Test in the U.S.Abbott Reports Strong Third-Quarter 2023 Results With Medical Device Sales up 15% Organically, Diagnostics up 6% Excluding COVID-19AMP Clinical Practice Committee Working Group on Liquid Biopsy Publishes Recommendations to Standardize Industry PracticesEurobio Introduces New Rapid Sequence Based Typing Test for HLA Testing Using Oxford Nanopore Long-Read TechnologyRevvity Expands Newborn Screening Mass Spectrometry Offering Through SCIEX PartnershipHCA Healthcare Partners with GRAIL to Offer Galleri Liquid Biopsy TestThermo Fisher Pays Big Multiple for Olink; Deal Expected to Accretive Year One Based on Substantial Cost/Revenue SynergiesProPhase Labs Announces Rapid Manufacturing Growth at CDMO Subsidiary Given Demand for Cold LozengesbioMérieux Receives CE-Marking for Blood Test for Traumatic Brain InjuryFollowing Failed Strategic Alternative Process; Biocept, Inc. Files for Chapter 7 Bankruptcy, Announces CEO/Board ResignationCharles River Laboratories Expands Access to Pediatric PDX Collection Following FDA/EMA Regulations Mandating Pediatric Testing for New Oncology DrugsInterVenn Biosciences Announces New Publication On Colorectal Cancer Multivariable Classifier Model; Aims to Launch Colon Cancer LDT in 2023Biocartis and APIS Expand Partnership in Breast Cancer with ESR1 Test Added to ASCO Guidelines in MayNew Naveris Studies Show Potential for Viral DNA as a MRD Marker in Oropharyngeal CancersT2 Biosystems Pre-Releases 3Q23 Results; Announces Additional FDA Submission for Sepsis TestInvitae Study Furthers Argument Supporting Hereditary Cancer Testing for all Breast Cancer PatientsFoundation Medicine Receives 2nd CDx Indication of the Week With FDA Approval for BRAF V600E mutations in Pfizer Combination Therapy for NSCLCCardio Diagnostic Holdings Announces New Lab for Proprietary Heart Disease Tests; Focused on Cost ReductionVeracyte Studies at CHEST Demonstrate Envisia’s Ability to Aid in Diagnosis of Interstitial Lung DiseaseEpigenomics AG Finalizes Asset Acquisition Agreement with New Day Diagnostics; Companies to Develop Next Generation Colon Cancer Blood TestFibronostics and Stone Diagnostics Partner to Advance Non-Invasive Liver Disease AssessmentClinical Microbiomics A/S and CosmosID Inc. Merge to Create the Global Leader in Microbiome Research ServicesStudy Demonstrates Pathnostics Guidance UTI Test Lowers Antibiotic Use and Hospitalizations in Complex UTI CasesNew Report from NCI Highlights Impact of COVID-19 on Rates of Cancer DiagnosisQuidel Pre-Releases 3Q23 Revenue; Strong Respiratory Revenue a Positive Read-Through for Other COVID-19 Test ManufacturersClass Action Complaint Against 23andMe, Inc. Filed in California District Court Accuses Company of Data NegligenceGE Healthcare and SOFIE Biosciences Partner on FAP Radiopharmaceuticals Shown to Be Highly Prognostic in Cancer StudiesSYNLAB Launches New Test to Differentiate Bipolar Disorder and Depression; Clinical Validation Shows High Accuracy Using Novel RNA BiomarkersLabcorp Launches New Blood Test for Early Alzheimer’s Detection; Follows Trend in Biomarker Development and Testing Following Leqembi ApprovalFujirebio and Sysmex Announce Bolstered Global Immunoassay Partnership; Deal Will Look to Leverage Combined StrengthsKarius Study Demonstrates the Ability for NGS Technology to Better Detect/Treat Pneumonia Pathogens in Immunocompromised PatientsTecan Sues QIAGEN and Invitae Over Next Generation Sequencing Sample Preparation PatentsAdvaMed Announces New Digital Health Tech DivisionFoundation One Announces FDA Approval for Companion Diagnostic Indication for Retevmo in Cancers With Rare RET Gene FusionsFoundation Medicine and Natera Launch Full Commercial Launch of FoundationOneTracker Utilizing Signatera for Treatment Response MonitoringExact Sciences to Release Full BLUE-C Study Results at ACGEU Regulators Rumored to Be on the Cusp of Ordering Illumina to Sell Grail23andMe Investigates Unauthorized Access to Customer AccountsNeway and Quest Diagnostics Partner to Improve Dialysis Patient CareRenalytix Receives Patents on Foundational Biomarkers for the KidneyIntelX.dkd TestKDx Diagnostics Issued Patents for Keratin 17 Biomarker in Bladder CancerA Deeper Dive Into Grail PATHFINDER Study Highlights Key Clinical Challenges; Unlikely to Be the Path to Broad Adoption and Insurance CoverageEntroGen Receives FDA Approval for CRCdx® RAS Mutation Detection Kit as Companion Diagnostic for Vectibix®Labcorp to Acquire Baystate Health’s Outreach Laboratory Business; PAMA Driving Continued Lab ConsolidationQIAGEN Launches QuantiFERON-EBV RUO Assay to Advance Research on Epstein-Barr Virus Immune ResponseCSPI Sues EpicGenetics Based Upon Claims of False and Misleading Statements on Fibromyalgia TestA New Study from Metabolomic Diagnostics Demonstrates the Potential for Blood Biomarkers to Improve Preeclampsia Risk Stratification in Pregnant WomenCastle Biosciences’ Study on DecisionDx-Melanoma Tool Demonstrates Ability to Predict Which Patients Should Receive Sentinel Node BiopsyNatera Study Demonstrates Ability of Signatera To Guide Clinical Decision Making in Unresectable NSCLC PatientsCue Health Study Shows High Correlation With POC COVID-19 Test and Laboratory PCREurofins Expands CDMO Capabilities in North America with New Canadian FacilityASCO Issues New Recommendations Aimed to Address Ovarian Toxicity in Cancer Clinical TrialsSerimmune Study Identifies Significant Biological Distinctions Associated with Long COVID-19Standard BioTools and SomaLogic Announce Merger; Investors Appear to Question Strategic Rationale Given Differing Business ModelsOxford BioDynamics Receives New PLA Code for EpiSwitch PSE Prostate Cancer TestFDA Grants Market Authorization for Invitae’s Common Hereditary Cancers Panel; Marks First FDA Approved Multi-Gene PanelPromega Partners with GSK to Develop MSI Companion Diagnostic IVD Kit for JemperliBostonGene Partners with Johns Hopkins University School of Medicine Furthering Strategic Research PartnershipsCastle Biosciences to Present New Data on DecisionDx-SCC at ASTRO 2023 Annual MeetingRenalytix kidneyintelX.dkd Test Priced at $950 by MedicareExact Sciences Subsidiary Genomic Health Settles Qi Tam Lawsuit for $32.5Advent International and Warburg Pincus Finalize Acquisition of Baxter’s BioPharma Solutions BusinessU.S. Supreme Court Declines to Hear CareDx’s Lawsuit Over Organ-Rejection Tests; Maintains Status Quo on Intellectual Property for Advanced Diagnostic PatentsNatera Submits First Module of PMA Application for Signatera as Companion Diagnostic for Muscle-Invasive Bladder CancerCastle Biosciences’ TissueCypher® Test Demonstrates Potential to Guide Clinical Decisions in Non-Dysplastic Barrett’s Esophagus PatientsFDA Issues Proposed Rule for Laboratory Developed Tests; Proposes Four Year Phase Out PlanEuropean Reference Laboratory SYNLAB Enters Investment Agreement with Private Equity Firm Cinven for Public Acquisition OfferPhenomix Sciences Receives Patent for Obesity Phenotyping TestAvantect Pancreatic Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services (CMS)MINT Subanalysis Demonstrates Mammaprint + BluePrint’s Ability To Predict Response to Neoadjuvant Chemotherapy in Stage 2&3 Lymph Node Positive Breast CancerNevisense Studies Demonstrate the Ability of the Device to Diagnose Skin Barrier Dysfunction Including Atopic Dermatitis in ChildrenVeracyte’s Afirma-Based Testing Reveals Novel Molecular Insights into Thyroid Cancer; Company Launches GRID Technology to Further Genetic Understanding of Thyroid CancerQIAGEN Expands Clinical Decision Support Software with AI-Enhanced Rare Disease Gene CoverageGRAIL Expand Access to Galleri® Multi-Cancer Early Detection Blood Test to Tufts Health Plan and Harvard Pilgrim Health Care in First Commercial Health Plan CollaborationSyneos Health Closes Transaction With Private Investment FirmsFDA Clears Thermo Fisher’s CgA Test for Rare Neuroendocrine TumorsHilary Gee Goeckner From Cancer Action Network Discusses New Biomarker LegislationStudy Shows Promising New Tau PET Tracer [18F]SNFT-1 Could Improve Early Alzheimer’s DetectionMyriad Survey Shows High Percentage of Women Pooly Informed on Breast Density Status/Risks and Family Health History Pertaining to Cancer RiskClario and CellCarta Collaborate to Improve Histopathology Services in Clinical TrialsBiocartis Group Announces Recapitalization and Wind Down Agreement; Deal Foreshadows Other Likely Future Debt Restructurings in Med-TechBiden-Harris Administration Invests $600 Million to Boost U.S. COVID-19 Test Manufacturing and Reopens COVIDTests.gov; Public Attitudes Toward COVID-19 Testing ChangingMDxHealth SA and University of Oxford Collaborate on Study to Evaluate the Correlation Between Genomic Prostate Score and Prostate Cancer ProgressionOxford BioDynamics Launches EpiSwitch Prostate Screening Blood Test in the USQuidelOrtho Receives First CLIA Waiver for a Flourescent Immunoassay Based COVID-19 Test; Still No Clarity on When the Emergency Use Authorizations for COVID-19 Tests Will ExpireCEO of Microba, Dr. Luke Reid Discusses the Future of the Microbiome for Clinical UseGinkgo Bioworks Partners With Republic of Madagascar to Enhance Biosecurity – Follows String of Biosecurity Announcements for the Company’s Concentric DivisionCharles River Laboratories Announces New Advanced Therapy Lab in UK to Better Serve CustomersValo Health and Novo Nordisk Sign Partnership to Harness Valo Health AI-driven Drug Discovery ToolsCareDx Notified that the SEC Will Not Pursue Enforcement Action Following InvestigationNew State Biomarker Legislation Advocated for by the Cancer Action Network Could Be a Game Changer for Expanding Commercial and Medicaid Access for Advanced DiagnosticsKaiser Strike Could Have Significant Impact on Patient Care; Sign of Growing Frustration Among Healthcare Workers on Labor Conditions:Changes in European In-Vitro Diagnostic Device Regulation Will Begin to Impact IVD Manufacturers; New Regulation Structure Will Increase Cost and Evidence Burden to Enter MarketCEO of Sherlock Biosciences, Bryan Dechairo Discusses the Potential Diagnostic Revolution With CRISPR DiagnosticsGM of Organ Health at Natera, Bernie Tobin Discusses Evolving Transplant Diagnostic MarketUNH Prior Authorization Changes To Date Unlikely To Significantly Impact Genetic Labs or Imaging Centers; Despite Lobbying Against Burdensome Barriers to Care, to Date There Has Been Minimal Impact
Illumina 3Q23 and Guidance Ugly, However Post-Grail Profitability Likely to Get Value Investors and Acquirers to Start Taking a LookOxford Nanopore Announces Strategic Acquisition of Northern Nanopore Instruments to Boost Solid-State Nanopore Development ProgramNo Suprises With Challenging 3Q23 and Outlook for Waters Following Peer Reports; Profitability Exceeds Expectations ThoughQIAGEN Announces Launch of New Sample-to-Answer Microbiome Research SolutionOxford Nanopore Announces Collaboration with Genomics England to Support 100,000 Genomes Project Rare Disease Initiative10x Genomics Shows Strong Momentum With Xenium Spatial Biology Platform Overcoming China and Macro HeadwindsRepligen Launches New TangenX SC Filtration Technology for BioprocessingNew QIAGEN and Element Biosciences Partnership Improves Workflow, Data Analytic Offerings for Element’s Disruptive AVITI SequencerSomalogic Expands Proteomics Testing Platform to Encompass 11,000 ProteinsIllumina Launches Next Generation of its Liquid Biopsy Assay for Cancer Genomic Profiling; Offers Key Workflow Enhancements and Increased SensitivityPacBio Expands Tertiary Analysis Ecosystem With Two New Genomic Analysis Software PartnersNCI Researchers Develop Innovative Approach to Significantly Boost T-Cell Therapies Against Solid TumorsBio-Techne Comes in Under Forecasts But Still Grows in Challenging Macro Backdrop; Levered to High Growth End Markets in Cell/Gene Therapy and Spatial BiologyOxford Nanopore and Fabric Genomics Collaborate on Pediatric Genomic Solution Set Using Nanopore Sequencing Technology and Fabric’s InformaticsRepligen 3Q23 Better Than Expected Among Backdrop of Biopharma Challenges; Optimistic Signs for Improvement in 2024Twist Bioscience Launches New “PCR Free” Multiplexing Chemistries for SequencingQIAGEN Weathers Macro Storm Better Than Most; QuantiFERON TB Driving Strong Diagnostic GrowthPacBio Defies Market Backdrop in 3Q23 With Revio and Onso Product Cycles Just StartingRevvity Faces Biopharma Challenges, COVID-19 Headwinds in 3Q23Bio-Rad Joins Peers With Ugly Life Science Results in 3Q23West Pharmaceutical Services Lowers Full-Year Outlook Citing Customer Inventory Control; COVID-19 Headwinds Abating and GLP-1 Represents Future Growth DriverBeckman Coulter and 10x Genomics Partner on Single Cell Automation SolutionsOxford Nanopore Partners With Saphetor To Improve Clinical Data InterpretationThermo Fisher 3Q23 Results and 2023 Guidance Forbodes Further Weakness in Life Science Tools; Management Anticipates Headwind Abatement in 2H24Bio-Techne to Showcase Spatial Biology Solutions in Cancer at SITC Meeting; Working Toward Multiomic Automated Solution Following Lunaphore AcquisitionQuanterix Enhances Alzheimer’s Offering With License to Johnson & Johnson’s p-Tau 217 AntibodiesDanaher 3Q23 Results Show Continued Headwinds From Bioprocessing, China, and COVID-19; Management Believes Inventory Draw Downs Will Lead to Improved Trends in 2024Ginkgo Bioworks Signs New Collaboration With Penn State To Monitor COVID-19 Variant Evolution in Wild AnimalsBioLife Solutions Pre-Releases Disappointing Q323 Due to Bioprocessing Slowdown; Company Also Announces Key Leadership TransitionsGinkgo Bioworks Announces Research and Biomonitoring Partnership with Serbian GovernmentThermo Fisher Scientific and Boehringer Ingelheim Partner to Advance Precision Cancer TherapiesOxford Nanopore Receives £70M Strategic Investment from bioMérieux; Signs New Research Collaboration with Mayo ClinicWaters Corporation Launches New OligoWorks™ SPE Kits in High-Growth Therapeutic MarketEurobio Introduces New Rapid Sequence Based Typing Test for HLA Testing Using Oxford Nanopore Long-Read TechnologyRevvity Expands Newborn Screening Mass Spectrometry Offering Through SCIEX PartnershipThermo Fisher Pays Big Multiple for Olink; Deal Expected to Accretive Year One Based on Substantial Cost/Revenue SynergiesGinkgo and Persephone Complete Collaboration on Toolkit to Create Custom Bacteroides for Life Science Research and Pharmaceutical DevelopmentMesa Labs Completes Acquisition of GKE-GmBH’s Sterilization Indicators Business; Should Accelerate Growth Following Recent HeadwindsDisruptive Benchtop Sequencer Manufacturer Element Biosciences Signs Partnership with Revvity on Workflow SolutionsIllumina Provides Update Following EC Order to Divest GRAILBIOCAPTIVA Launches New Study to See if BioCaptis cfDNA Enrichment Device Can Enhance Accuracy of Lung Fluid BiopsiesEuropean Commission Orders Illumina to Unwind GRAIL Acquisition; Deal Will Unlock Near-Term Accretion but Valuation a ConcernQL AG and Ginkgo Bioworks Collaborate to Foster Sustainable Dairy Protein ProductionPacBio Unveils New Data Analysis Tool for Whole Genome Sequencing; Continues to Up its Game in NGS MarketTecan Sues QIAGEN and Invitae Over Next Generation Sequencing Sample Preparation Patents10x Genomics Announces UPC Has Declined to Issue Second Preliminary Injunction Against NanoString in Spatial Genomics DisputeNanoString Pre-Releases Positive 3Q23 Results Showing Accelerating Spatial Biology Revenue and Announces Restructuring; Focus Still on Freedom to OperateTerumo BCT and BioCentriq Partner to Develop More Efficient CAR-T Cell Manufacturing; Plan to Publish Data at Upcoming Conferences in 2024Ginkgo Bioworks and Northeastern University to Aid in CDC Funded Program for Epidemic Monitoring and PreventionTwist Bioscience Announces Antibody Discovery Agreement with Bayer Worth Up to $188 MillionBruker Announces Majority Investment in Swiss Spectroscopy Gas Analyzer CompanyStandard BioTools and SomaLogic Announce Merger; Investors Appear to Question Strategic Rationale Given Differing Business ModelsBruker Corporation Completes Acquisition of PhenomeXA*STAR’s Genome Institute of Singapore, NanoString, and Next Level Genomics Establish Joint Lab for Spatial Genomics ResearchAngle’s Parsortix System Outperforms Density Centrifugation Method For Isolating Tumor CellsNosh.bio Collaborates with Ginkgo Bioworks to Improve Flavor of Fungal Meat AlternativesnRichDX® Launches CTC Enrichment Kit on Revolution Sample Prep SystemUPC Ruling in Favor of 10x Genomics Leads to Injunction Against NanoString in 17 EU Countries; Spatial Genomics Legal Battle Heating Up With U.S. Trials PendingIntegrated DNA Technologies Develops First Sequencing Chemistries Specifically Designed for the Potentially Disruptive Ultima UG 100 SequencerConcentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease SpilloverQIAGEN Expands Clinical Decision Support Software with AI-Enhanced Rare Disease Gene CoverageRevvity Introduces Pin-point™ Base Editing Reagents to Researchers to Accelerate Genomic DiscoveryEnsovi Partners with Ginkgo Bioworks to Advance Sustainable BiomanufacturingBionano Genomics Highlights Peer Reviewed Study Showing High Concordance Between Optical Genome Mapping (OGM) and Chromosomal Microarray AnalysisAbcam Founder Writes Letter Expressing Dissatisfaction with Danaher Acquisition; Campaign Unlikely to SucceedGinkgo Bioworks Collaborates with Pfizer for RNA-Based Drug DiscoveryTwist Bioscience and IMIDomics Join Forces for Immune-Mediated Inflammatory Disease Antibody DiscoveryRecent Studies Published in Nature Demonstrate the Utility of RareCyte’s Orion Spatial Biology PlatformBio-Techne Integrates Maurice Chromotography Platform With Thermo Scientific Chromeleon Data SystemRepligen Acquires Swedish Company Bolstering Fluid Management Offering to Bioprocessing CustomersCharles River Launches New Gene Therapy Manufacturing with Lentivation™ Platform; Dramatically Shortens Manufacturing Timelines908 Devices Begins Roll-Out of Biothreat Detection Systems in Support of Department of Defense AVCAD ProgramQIAGEN Offers New Sustainable Solutions for its Market Leading DNA Extraction TechnologiesCEO of Microba, Dr. Luke Reid Discusses the Future of the Microbiome for Clinical UseValo Health and Novo Nordisk Sign Partnership to Harness Valo Health AI-driven Drug Discovery ToolsNew State Biomarker Legislation Advocated for by the Cancer Action Network Could Be a Game Changer for Expanding Commercial and Medicaid Access for Advanced DiagnosticsKaiser Strike Could Have Significant Impact on Patient Care; Sign of Growing Frustration Among Healthcare Workers on Labor Conditions:Singular Genomics CEO, Drew Spaventa Discusses Disruptive Technology in Sequencing Market
Ultromics Receives HOPPS Code for EchoGo Heart Failure in Outpatient Setting Following Inpatient Reimbursement Earlier this YearLabcorp to Offer New Fertility/Family Building Service Offering to Employers/Health Plans Through Ovia Health SubsidiaryAbbott Study Shows its Healthy Food Rx Program Can Improve Outcomes Around DiabetesHims & Hers Momentum Train Continues With 56% Subscriber Growth and 19% Growth in Average Revenue Per Order Despite Weakening Consumer BackdropMicrobiome Wellness Company Viome Acquires Multi-omics Wellness Company Naring Health To Combine Expertise and Expand OfferingsGE Healthcare Study Shows that AI and Imaging May Play a Role in Checkpoint Inhibitor Selection for Cancer PatientsBilling Software Leader Waystar to Delay IPO Based Upon Market Conditions; Shows Continuing Challenging Environment for Healthcare IT ProvidersMcKesson Beats in 3Q23, GLP-1 Drives Increased Pharma Segment Revenue and Increased Prescription Technology Solutions Due to Prior Authorization Service DemandDigital Health and Disease Management Company DarioHealth Launches Blood Sugar Meter Designed for Use With iPhone 15PacBio Expands Tertiary Analysis Ecosystem With Two New Genomic Analysis Software PartnersTeraRecon Collaboration With Avicenna.AI Will Add Two New AI-Based Imaging Interpretation Applications in Pulmonary Embolism and Aortic Dissection to Eureka Software PlatformFresenius Announces Apollo Database Project to Glean Clinical Insights From 540,000 Dialysis PatientsTeladoc Health Focuses On Profitability And Misses Revenue TargetsMetabolic Health App Developer, Signos, Raises $20M in Series B Funding Including Investment from Dexcom VenturesLucida Medical Gets CE Mark for Prostate MRI CAD Technology in Europe Using AI; Data Shows Impressive Ability to Improve Sensitivity and Reduce Unnecessary BiopsiesTelehealth Solutions Provider Headway Raises $125 Million in Series C Round; Plans Continued Expansion in Mental HealthDOD Selects Amwell Converge Platform for Telehealth Offering and Digital Care SolutionsSpring Health Launches Atlas AI Tool to Empower HR Leaders on Behavioral Health Data ManagementAI Billing Company Waystar Files to Go Public; Ends Drought of Healthcare IT IPOsEvidation Receives BARDA Contract to Use Wearable Devices in Flu MonitoringMedacta Study in Shoulder Arthroplasty Further Demonstrates the Potential of Augmented Reality in OrthopedicsGoodRx Partners With Navitus on Collaboration to Improve Drug Price Transparency at PharmaciesDaVita Releases Statement Following Stock Sell-Off on Novo Nordisk’s GLP-1 Study AnnouncementiCAD CEO Dana Brown Discusses Future of AI in Imaging TechnologiesMendel Launches Hypercube AI-Tool for Analyzing Life Sciences and Healthcare DataHighmark Expands Access to Spring Health Powered Mental Health ProgramTeraRecon and FEops Announce Collaboration for Structural Heart Planning ProceduresButterfly Network Introduces New Education Support Tools23andMe Investigates Unauthorized Access to Customer AccountsTeladoc Health Teams Up with Sword Health to Enhance Musculoskeletal Health CareGE Healthcare Integrates Caption Guidance Heart Failure AI Technology Into Ultrasound SolutionsNeway and Quest Diagnostics Partner to Improve Dialysis Patient CareNestle/Amwell Partnership Matches Amwell’s Automated Care Solutions with Nestle Nutrition ExpertiseVerily Launches Viewpoint Workbench to Expedite Biomedical ResearchCommure and Athelas to Merge to Gain Scale and Drive Efficiency; Consolidation an Increasing Trend in Healthcare ITGinkgo Bioworks and Northeastern University to Aid in CDC Funded Program for Epidemic Monitoring and PreventionCovetrus Signs Partnership with Vetcor Making them the Primary Provider of Vet Software SolutionsSonde Health and Together Team Up to Enhance Virtual Mental Health MonitoringButterfly Network and Razom Partner to Expand Access to Butterly iQ+ Ultrasound Technology in UkraineHealthTap and Health Gorilla Join Forces to Facilitate Access to Medical RecordsFresenius Accused of Medical Fraud in New Qui Tam LawsuitBostonGene Partners with Johns Hopkins University School of Medicine Furthering Strategic Research PartnershipsSword Health and Costco Health Solutions Partner on Digital Physical Therapy and Lifestyle SolutionsAnumana Receives FDA 510k Approval for New AI Powered Heart Failure Diagnosis TechnologyLyra to Launch Benefit Ecosystem Tool in January 2024Boehringer Ingelheim and ZEISS Partner to Prevent Vision Loss; Partnership Aims to Create AI Tools and Early Predictive Markers for Eye DiseaseFollowing Lobbying by Radiologist Societies, CMS Allows for Billing of Multiple Cardiac MRI ProceduresSpring Health Expands Substance Use Disorder Support Services Through Partnership with Eleanor HealthChronic Disease Management Company Lark Health Expands Personalized Weight Management Solutions to Support GLP-1 Medication DemandsKomodo Health Introduces MapLab™: An Integrated Solution for Healthcare and Life Sciences InsightsTeraRecon’s Eureka Clinical AI Platform Automates Cardiovascular Disease Diagnosis Utilizing Advanced AIBeacon Receives FDA Approval for Dreem 3S; Facilitates Collection of High Quality Sleep Data in the Home SettingKidney Disease Management Company Renalytix Reports Full Year Results; Mitigating Cash Burn Key to Future SuccessAugmedix Introduces Augmedix Go: A Clinician-Controlled Mobile App Using Generative AI for Automated Medical NotesVirtual Primary Care Provider HealthTap Launches Enhanced Version of Dr.A.I. Which Automates Patient InterviewsSomatus Receives Validation of Claim that it Reduces Hospital Readmissions for Patients With Kidney DiseaseFDA Issues Final Guidance Document on Cybersecurity Requirements for Premarket Device SubmissionsCardiosense Begins Enrollment in Nationwide Heart Failure StudyNICE Conditionally Recommends AliveCor’s KardiaMobile for Measuring Cardiac QT Intervals in Adults Taking Antipsychotic MedicationCostco Continues Trend Among Retailers to Offer Primary Care Services Utilizing Telehealth Networks; Could Change Care Delivery in the United StatesHinge Health Launches Enhancements to Women’s Pelvic Health ProgramAxxess and Gateway Home Health Coding & Consulting LLC Form Strategy PartnershipGinkgo Bioworks Partners With Republic of Madagascar to Enhance Biosecurity – Follows String of Biosecurity Announcements for the Company’s Concentric DivisionValo Health and Novo Nordisk Sign Partnership to Harness Valo Health AI-driven Drug Discovery ToolsNew State Biomarker Legislation Advocated for by the Cancer Action Network Could Be a Game Changer for Expanding Commercial and Medicaid Access for Advanced DiagnosticsKaiser Strike Could Have Significant Impact on Patient Care; Sign of Growing Frustration Among Healthcare Workers on Labor Conditions:How a Robot Could Be Reading Your Next Mammogram – AI Tools in Development at Google Health and iCAD Poised to Improve Care, Reduce Costs, and Perhaps Ultimately Replace Human Interpretation
Dentsply Sirona Investor Day Focuses on Streamlining Strategy and Utilizing Digital Assets to Drive 15% Earnings Growth CAGR From 2023-2026IDEXX Launches New Rapid Antibody Test for Leishmaniosis on SNAP 4Dx PlatformElanco Animal Health Suprises to Upside Following Mixed Commentary from Animal Health Peers, Concerns Over Declining Vet VisitsDentsply Sirona Follows Peers With Challenging 3Q23; Notes Survey Data Showing Declining Global Volumes and Increased CancellationsZoetis Fares Better Than Rival IDEXX in 3Q23 With Solid Companion Animal GrowthEnvista Earnings Show Dental Market Macro Headwinds; Clear Aligner Strength a Bright SpotZimVie’s 3Q23 Better than Tepid Expectations, but Elective Procedure Headwinds in Dental Likely to Worsen and U.S. Spine Competition Unlikely to AbateIDEXX 3Q23 Shows Beginning Signs of a Vet Consumer Slowdown; Pricing Drives Majority of Growth in Quarter, But is it SustainableAlign Sees Significant Slowdown in 3Q23 and Guides to Ugly 4Q23; Is it a Harbinger for Elective Procedures, Competition, or Both?Alveo and Corteva Announce Partnership for Handheld, Point-of-Care Agriculture Testing SolutionDentsply Sirona Launches New Outcome Simulation Tool; Competes with Similar Offerings from Market Leader Align TechnologyNew Dental Care Study Using Delta Dental Claims Shows Substantial Reduction in Preventive Care Visits Long After Initial Stages of the Pandemic Leading to Increased Interventions NowZimVie Announces Launch of Azure Product Solutions to Strengthen Offering to Dental LaboratoriesOraQ Launches AI Driven Support Tool For Dentists in U.S.; Joins Increasingly Crowded Field of Solution ProvidersQL AG and Ginkgo Bioworks Collaborate to Foster Sustainable Dairy Protein ProductionZimVie Launches New Bio-Active Membrane for Dental SurgerySonendo Pre-Releases In-Line Preliminary Financial Results for Q3 2023; However, Guidance Implies Improving 4Q TrendSonendo Announces Two New DSO Partnerships for its GentleWave SystemCovetrus Signs Partnership with Vetcor Making them the Primary Provider of Vet Software SolutionsSmileDirectClub Files for Chapter 11 Bankruptcy Protection, Announces Financial Restructuring To Fund Ongoing OperationsCorteva Files Lawsuit Against Inari USA Alleging Intellectual Property Theft and Patent Violations for Bio-Engineered SeedsConcentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease SpilloverSonendo Introduces Second Generation CleanFlow™ Procedure Instrument for Enhanced Root Canal TreatmentHarpe Bioherbicide Solutions Licenses CRISPR-Cas9 Technology from Corteva Bioscience and the Broad Institute of MIT/Harvard to Develop New Crop Systems Tolerant to Harpe BioherbicidesFDA’s CDRH Division Releases Draft Strategic Plan on International Regulatory Harmonization to Lower Redundancy and Reduce Burden on Device ManufacturersDentsply Sirona Highlights New Technologies at Las Vegas Professional Education EventNew State Biomarker Legislation Advocated for by the Cancer Action Network Could Be a Game Changer for Expanding Commercial and Medicaid Access for Advanced DiagnosticsThere is an Increasing Trend Toward Increased Dental Coverage for Medicaid Patients Across the United StatesKaiser Strike Could Have Significant Impact on Patient Care; Sign of Growing Frustration Among Healthcare Workers on Labor Conditions:Align Technology Facing Emboldened Established Competitors and New Venture Backed Competition; Will it Maintain its Market Dominance in Clear Orthodontics?Mars Petcare Quietly Laying Strategic Groundwork to Be a Major Player in Veterinary Diagnostic Market – Could it Impact Market Leaders Idexx and Zoetis?

State of UtahRev. 1343F05
TERMS OF USE MEDTECH GENIE 

Version Date: September 08, 2023

TERMS OF USE AGREEMENT

This Terms of Use Agreement (“Agreement”), constitutes a legally binding agreement made between you, whether personally or on behalf of an entity (“user” or “you”) and MedTech Genie LLC and its affiliated companies, Websites, applications and tools (collectively, MedTech Genie LLC, “Company” or “we” or “us” or “our”), concerning your access to and use of the www.medtechgenie.com Website(s) as well as any other media form, media channel, mobile website or mobile application related or connected thereto (collectively, the “Sites”). The Sites provide the following service: Online publication serving the medical industry. (“Company Services”). Supplemental terms and conditions or documents that may be posted on the Sites from time to time, are hereby expressly incorporated into this Agreement by reference.

Company makes no representation that the Sites is appropriate or available in other locations other than where it is operated by Company. The information provided on the Sites is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Company to any registration requirement within such jurisdiction or country. Accordingly, those persons who choose to access the Sites from other locations do so on their own initiative and are solely responsible for compliance with local laws, if and to the extent local laws are applicable.

All users who are minors in the jurisdiction in which they reside (generally under the age of 18) are not permitted to register for the Sites or use the Company Services.

YOU ACCEPT AND AGREE TO BE BOUND BY THIS AGREEMENT BY ACKNOWLEDGING SUCH ACCEPTANCE DURING THE REGISTRATION PROCESS (IF APPLICABLE) AND ALSO BY CONTINUING TO USE THE SITES. IF YOU DO NOT AGREE TO ABIDE BY THIS AGREEMENT, OR TO MODIFICATIONS THAT COMPANY MAY MAKE TO THIS AGREEMENT IN THE FUTURE, DO NOT USE OR ACCESS OR CONTINUE TO USE OR ACCESS THE COMPANY SERVICES OR THE SITES.

PURCHASES PAYMENT

MedTech Genie LLC may offer free trial or sample of our products or services. The duration of the free trial period and all other details of the offer will be posted on our Sites If you wish to try our free options please read through them carefully first. MedTech Genie LLC will bill you through a payment provider for our Services. By using our paid options you agree to pay MedTech Genie LLC all charges at the prices then in effect for the products or services you or other persons using your billing account may purchase, and you authorize MedTech Genie LLC to charge your chosen payment provider for any such purchases. You agree to make payment using that selected payment method. If you have ordered a product or service that is subject to recurring charges then you agree to us charging your payment method on a recurring basis, without requiring your prior approval from you for each recurring charge until such time as you cancel the applicable product or service. MedTech Genie LLC reserves the right to correct any errors or mistakes in pricing that it makes even if it has already requested or received payment. Sales tax will be added to the sales price of purchases as deemed required by Company. Company may change prices at any time. All payments shall be in U.S. dollars.

REFUND AND RETURN

All sales are final and no refunds shall be issued.

USER REPRESENTATIONS

Regarding Your Registration

By using the MedTech Genie LLC Services, you represent and warrant that:

A. all registration information you submit is truthful and accurate;

B. you will maintain the accuracy of such information;

C. you will keep your password confidential and will be responsible for all use of your password and account;

D. you are not a minor in the jurisdiction in which you reside, or if a minor, you have received parental permission to use our Sites; and

E. your use of the Company Services does not violate any applicable law or regulation.

You also agree to: (a) provide true, accurate, current and complete information about yourself as prompted by the Sites' registration form and (b) maintain and promptly update registration data to keep it true, accurate, current and complete. If you provide any information that is untrue, inaccurate, not current or incomplete, or Company has reasonable grounds to suspect that such information is untrue, inaccurate, not current or incomplete, Company has the right to suspend or terminate your account and refuse any and all current or future use of the Sites (or any portion thereof).

We reserve the right to remove or reclaim or change a user name you select if we determine appropriate in our discretion, such as when the user name is obscene or otherwise objectionable or when a trademark owner complains about a username that does not closely relate to a user's actual name.

Regarding Content You Provide

We may invite you to chat or participate in blogs, message boards, online forums and other functionality and may provide you with the opportunity to create, submit, post, display, transmit, perform, publish, distribute or broadcast content and materials to our Sites and/or to or via the Sites' forms, emails, chat agents, popups, including, without limitation, text, writings, video, audio, photographs, graphics, comments, suggestions or personally identifiable information or other material (collectively "Contributions"). Any Contributions you transmit to MedTech Genie LLC will be treated as non-confidential and non-proprietary. When you create or make available a Contribution, you thereby represent and warrant that:

A. the creation, distribution, transmission, public display and performance, accessing, downloading and copying of your Contribution does not and will not infringe the proprietary rights, including but not limited to the copyright, patent, trademark, trade secret or moral rights of any third party;

B. you are the creator and owner of or have the necessary licenses, rights, consents, releases and permissions to use and to authorize MedTech Genie LLC and the Sites' users to use your Contributions as necessary to exercise the licenses granted by you under this Agreement;

C. you have the written consent, release, and/or permission of each and every identifiable individual person in the Contribution to use the name or likeness of each and every such identifiable individual person to enable inclusion and use of the Contribution in the manner contemplated by our Sites;

D. your Contribution is not obscene, lewd, lascivious, filthy, violent, harassing or otherwise objectionable (as determined by MedTech Genie LLC), libelous or slanderous, does not ridicule, mock, disparage, intimidate or abuse anyone, does not advocate the violent overthrow of any government, does not incite, encourage or threaten physical harm against another, does not violate any applicable law, regulation, or rule, and does not violate the privacy or publicity rights of any third party;

E. your Contribution does not contain material that solicits personal information from anyone under 18 or exploit people under the age of 18 in a sexual or violent manner, and does not violate any federal or state law concerning child pornography or otherwise intended to protect the health or well-being of minors;

F. your Contribution does not include any offensive comments that are connected to race, national origin, gender, sexual preference or physical handicap;

G. your Contribution does not otherwise violate, or link to material that violates, any provision of this Agreement or any applicable law or regulation.

CONTRIBUTION LICENSE

By posting Contributions to any part of the Sites, or making them accessible to the Sites by linking your account to any of your social network accounts, you automatically grant, and you represent and warrant that you have the right to grant, to MedTech Genie LLC an unrestricted, unconditional, unlimited, irrevocable, perpetual, non-exclusive, transferable, royalty-free, fully-paid, worldwide right and license to host, use, copy, reproduce, disclose, sell, resell, publish, broadcast, retitle, archive, store, cache, publicly perform, publicly display, reformat, translate, transmit, excerpt (in whole or in part) and distribute such Contributions (including, without limitation, your image and voice) for any purpose, commercial, advertising, or otherwise, to prepare derivative works of, or incorporate into other works, such Contributions, and to grant and authorize sublicenses of the foregoing. The use and distribution may occur in any media formats and through any media channels. Such use and distribution license will apply to any form, media, or technology now known or hereafter developed, and includes our use of your name, company name, and franchise name, as applicable, and any of the trademarks, service marks, trade names and logos, personal and commercial images you provide. Company does not assert any ownership over your Contributions; rather, as between us and you, subject to the rights granted to us in this Agreement, you retain full ownership of all of your Contributions and any intellectual property rights or other proprietary rights associated with your Contributions. We will not use your contribution in a way that infringes on your rights and always process your personal information lawfully and with your consent.

Company has the right, in our sole and absolute discretion, to (i) edit, redact or otherwise change any Contributions, (ii) re-categorize any Contributions to place them in more appropriate locations or (iii) pre-screen or delete any Contributions that are determined to be inappropriate or otherwise in violation of this Agreement.

By uploading your Contributions to the Sites, you hereby authorize Company to grant to each end user a personal, limited, no-transferable, perpetual, non-exclusive, royalty-free, fully-paid license to access, download, print and otherwise use your Contributions for their internal purposes and not for distribution, transfer, sale or commercial exploitation of any kind.

MOBILE APPLICATION LICENSE

Use License

If you are accessing the MedTech Genie LLC  Services via a mobile application, then MedTech Genie LLC  grants you a revocable, non-exclusive, non-transferable, limited right to install and use the application on wireless handsets owned and controlled by you, and to access and use the application on such devices strictly in accordance with the terms and conditions of this license. You shall use the application strictly in accordance with the terms of this license and shall not: (a) decompile, reverse engineer, disassemble, attempt to derive the source code of, or decrypt the application; (b) make any modification, adaptation, improvement, enhancement, translation or derivative work from the application; (c) violate any applicable laws, rules or regulations in connection with your access or use of the application; (d) remove, alter or obscure any proprietary notice (including any notice of copyright or trademark) of Company or its affiliates, partners, suppliers or the licensors of the application; (e) use the application for any revenue generating endeavor, commercial enterprise, or other purpose for which it is not designed or intended; (f) make the application available over a network or other environment permitting access or use by multiple devices or users at the same time; (g) use the application for creating a product, service or software that is, directly or indirectly, competitive with or in any way a substitute for the application; (h) use the application to send automated queries to any Sites or to send any unsolicited commercial e-mail; or (i) use any proprietary information or interfaces of MedTech Genie LLC or other intellectual property of MedTech Genie LLC in the design, development, manufacture, licensing or distribution of any applications, accessories or devices for use with the application.

Terms Applicable to Apple and Android Devices

The following terms apply when you use a mobile application obtained from either the Apple Store or Google Play to access the MedTech Genie LLC Services. You acknowledge that this Agreement is concluded between you and MedTech Genie LLC only, and not with Apple Inc. or Google, Inc. (each an “App Distributor”), and MedTech Genie LLC, not an App Distributor, is solely responsible for the MedTech Genie LLC application and the content thereof. (1) SCOPE OF LICENSE: The license granted to you for the MedTech Genie LLC application is limited to a non-transferable license to use the MedTech Genie LLC application on a device that utilizes the Apple iOS or Android operating system, as applicable, and in accordance with the usage rules set forth in the applicable App Distributor terms of service. (2) MAINTENANCE AND SUPPORT: MedTech Genie LLC is solely responsible for providing any maintenance and support services with respect to the MedTech Genie LLC application, as specified in this Agreement, or as required under applicable law. You acknowledge that each App Distributor has no obligation whatsoever to furnish any maintenance and support services with respect to the MedTech Genie LLC application. (3) WARRANTY: MedTech Genie LLC is solely responsible for any product warranties, whether express or implied by law, to the extent not effectively disclaimed. In the event of any failure of the MedTech Genie LLC  application to conform to any applicable warranty, you may notify an App Distributor, and the App Distributor, in accordance with its terms and policies, may refund the purchase price, if any, paid for the MedTech Genie LLC application, and to the maximum extent permitted by applicable law, an App Distributor will have no other warranty obligation whatsoever with respect to the MedTech Genie LLC application, and any other claims, losses, liabilities, damages, costs or expenses attributable to any failure to conform to any warranty will be MedTech Genie LLC  sole responsibility. (4) PRODUCT CLAIMS: You acknowledge that MedTech Genie LLC, not an App Distributor, is responsible for addressing any claims of yours or any third party relating to the MedTech Genie LLC application or your possession and/or use of the MedTech Genie LLC application, including, but not limited to: (i) product liability claims; (ii) any claim that the MedTech Genie LLC application fails to conform to any applicable legal or regulatory requirement; and (iii) claims arising under consumer protection or similar legislation. (5) INTELLECTUAL PROPERTY RIGHTS: You acknowledge that, in the event of any third party claim that the MedTech Genie LLC application or your possession and use of the MedTech Genie LLC application infringes a third party’s intellectual property rights, the App Distributor will not be responsible for the investigation, defense, settlement and discharge of any such intellectual property infringement claim. (6) LEGAL COMPLIANCE: You represent and warrant that (i) you are not located in a country that is subject to a U.S. government embargo, or that has been designated by the U.S. government as a “terrorist supporting” country; and (ii) you are not listed on any U.S. government list of prohibited or restricted parties. (7) THIRD PARTY TERMS OF AGREEMENT: You must comply with applicable third party terms of agreement when using the MedTech Genie LLC application, e.g., if you have a VoIP application, then you must not be in violation of their wireless data service agreement when using the MedTech Genie LLC application. (8) THIRD PARTY BENEFICIARY: MedTech Genie LLC and you acknowledge and agree that the App Distributors, and their subsidiaries, are third party beneficiaries of this Agreement, and that, upon your acceptance of the terms and conditions of this Agreement, each App Distributor will have the right (and will be deemed to have accepted the right) to enforce this Agreement against you as a third party beneficiary thereof.

SUBMISSIONS

You acknowledge and agree that any questions, comments, suggestions, ideas, feedback or other information about the Sites or the MedTech Genie LLC Services ("Submissions") provided by you to MedTech Genie LLC are non-confidential and MedTech Genie LLC (as well as any designee of Company) shall be entitled to the unrestricted use and dissemination of these Submissions for any purpose, commercial or otherwise, without acknowledgment or compensation to you.

PROHIBITED ACTIVITIES

You may not access or use the Sites for any other purpose other than that for which MedTech Genie LLC makes it available. The Sites may not be used in connection with any commercial endeavors except those that are specifically endorsed or approved by MedTech Genie LLC. Prohibited activity includes, but is not limited to:

A. attempting to bypass any measures of the Sites designed to prevent or restrict access to the Sites, or any portion of the Sites

B. attempting to impersonate another user or person or using the username of another user

C. criminal or tortious activity

D. deciphering, decompiling, disassembling or reverse engineering any of the software comprising or in any way making up a part of the Sites

E. deleting the copyright or other proprietary rights notice from any Sites' content

F. engaging in any automated use of the system, such as using any data mining, robots or similar data gathering and extraction tools

G. except as may be the result of standard search engine or Internet browser usage, using or launching, developing or distributing any automated system, including, without limitation, any spider, robot (or "bot"), cheat utility, scraper or offline reader that accesses the Sites, or using or launching any unauthorized script or other software

H. harassing, annoying, intimidating or threatening any Company employees or agents engaged in providing any portion of the Company Services to you

I. interfering with, disrupting, or creating an undue burden on the Sites or the networks or services connected to the Sites

J. making any unauthorized use of the Company Services, including collecting usernames and/or email addresses of users by electronic or other means for the purpose of sending unsolicited email, or creating user accounts by automated means or under false pretenses

K. selling or otherwise transferring your profile

L. systematic retrieval of data or other content from the Sites to create or compile, directly or indirectly, a collection, compilation, database or directory without written permission from Company

M. tricking, defrauding or misleading Company and other users, especially in any attempt to learn sensitive account information such as passwords

N. using any information obtained from the Sites in order to harass, abuse, or harm another person

O. using the Company Services as part of any effort to compete with Company or to provide services as a service bureau

P. using the Sites in a manner inconsistent with any and all applicable laws and regulations

INTELLECTUAL PROPERTY RIGHTS

The content on the Sites (“MedTech Genie LLC Content”) and the trademarks, service marks and logos contained therein (“Marks”) are owned by or licensed to MedTech Genie LLC, and are subject to copyright and other intellectual property rights under United States and foreign laws and international conventions. MedTech Genie LLC Content, includes, without limitation, all source code, databases, functionality, software, Sites' designs, audio, video, text, photographs and graphics. All MedTech Genie LLC graphics, logos, designs, page headers, button icons, scripts and service names are registered trademarks, common law trademarks or trade dress of MedTech Genie LLC in the United States and/or other countries. MedTech Genie LLC trademarks and trade dress may not be used, including as part of trademarks and/or as part of domain names, in connection with any product or service in any manner that is likely to cause confusion and may not be copied, imitated, or used, in whole or in part, without the prior written permission of the MedTech Genie LLC.

MedTech Genie LLC Content on the Sites is provided to you “AS IS” for your information and personal use only and may not be used, copied, reproduced, aggregated, distributed, transmitted, broadcast, displayed, sold, licensed, or otherwise exploited for any other purposes whatsoever without the prior written consent of the respective owners. Provided that you are eligible to use the Sites, you are granted a limited license to access and use the Sites and the MedTech Genie LLC Content and to download or print a copy of any portion of the MedTech Genie LLC Content to which you have properly gained access solely for your personal, non-commercial use. MedTech Genie LLC reserves all rights not expressly granted to you in and to the Sites and MedTech Genie LLC Content and Marks.

THIRD PARTY WEBSITES AND CONTENT

The Sites contains (or you may be sent through the Sites or the MedTech Genie LLC Services) links to other websites ("Third Party Websites") as well as articles, photographs, text, graphics, pictures, designs, music, sound, video, information, applications, software and other content or items belonging to or originating from third parties (the "Third Party Content"). Such Third Party Websites and Third Party Content are not investigated, monitored or checked for accuracy, appropriateness, or completeness by us, and we are not responsible for any Third Party accessed through the Sites or any Third Party Content posted on, available through or installed from the Sites, including the content, accuracy, offensiveness, opinions, reliability, privacy practices or other policies of or contained in the Third Party Websites or the Third Party Content. Inclusion of, linking to or permitting the use or installation of any Third Party Websites or any Third Party Content does not imply approval or endorsement thereof by us. If you decide to leave the Sites and access the Third Party Websites or to use or install any Third Party Content, you do so at your own risk and you should be aware that our terms and policies no longer govern. You should review the applicable terms and policies, including privacy and data gathering practices, of any websites to which you navigate from the Sites or relating to any applications you use or install from the Sites. Any purchases you make through Third Party Websites will be through other websites and from other companies, and MedTech Genie LLC takes no responsibility whatsoever in relation to such purchases which are exclusively between you and the applicable third party.

SITE MANAGEMENT

MedTech Genie LLC reserves the right but does not have the obligation to:

A. monitor the Sites for violations of this Agreement;

B. take appropriate legal action against anyone who, in MedTech Genie LLC sole discretion, violates this Agreement, including without limitation, reporting such user to law enforcement authorities;

C. in MedTech Genie LLC sole discretion and without limitation, refuse, restrict access to or availability of, or disable (to the extent technologically feasible) any user’s contribution or any portion thereof that may violate this Agreement or any MedTech Genie LLC policy;

D. in Company’s sole discretion and without limitation, notice or liability to remove from the Sites or otherwise disable all files and content that are excessive in size or are in any way burdensome to MedTech Genie LLC 's systems;

E. otherwise manage the Sites in a manner designed to protect the rights and property of MedTech Genie LLC and others and to facilitate the proper functioning of the Sites.

TERM AND TERMINATION

This Agreement shall remain in full force and effect while you use the Sites or are otherwise a user or member of the Sites, as applicable. You may terminate your use or participation at any time, for any reason, by following the instructions for terminating user accounts in your account settings, if available, or by contacting us using the contact information below.

WITHOUT LIMITING ANY OTHER PROVISION OF THIS AGREEMENT, COMPANY RESERVES THE RIGHT TO, IN COMPANY’S SOLE DISCRETION AND WITHOUT NOTICE OR LIABILITY, DENY ACCESS TO AND USE OF THE SITES AND THE COMPANY SERVICES, TO ANY PERSON FOR ANY REASON OR FOR NO REASON AT ALL, INCLUDING WITHOUT LIMITATION FOR BREACH OF ANY REPRESENTATION, WARRANTY OR COVENANT CONTAINED IN THIS AGREEMENT, OR OF ANY APPLICABLE LAW OR REGULATION, AND COMPANY MAY TERMINATE YOUR USE OR PARTICIPATION IN THE SITES AND THE COMPANY SERVICES, DELETE YOUR PROFILE AND ANY CONTENT OR INFORMATION THAT YOU HAVE POSTED AT ANY TIME, WITHOUT WARNING, IN COMPANY’S SOLE DISCRETION.

In order to protect the integrity of the Sites and Company Services, Company reserves the right at any time in its sole discretion to block certain IP addresses from accessing the Sites and Company Services.

Any provisions of this Agreement that, in order to fulfill the purposes of such provisions, need to survive the termination or expiration of this Agreement, shall be deemed to survive for as long as necessary to fulfill such purposes.

YOU UNDERSTAND THAT CERTAIN STATES ALLOW YOU TO CANCEL THIS AGREEMENT, WITHOUT ANY PENALTY OR OBLIGATION, AT ANY TIME PRIOR TO MIDNIGHT OF COMPANY’S THIRD BUSINESS DAY FOLLOWING THE DATE OF THIS AGREEMENT, EXCLUDING SUNDAYS AND HOLIDAYS. TO CANCEL, CALL A COMPANY CUSTOMER CARE REPRESENTATIVE DURING NORMAL BUSINESS HOURS USING THE CONTACT INFORMATION LISTING BELOW IN THIS AGREEMENT OR BY ACCESSING YOUR ACCOUNT SETTINGS. THIS SECTION APPLIES ONLY TO INDIVIDUALS RESIDING IN STATES WITH SUCH LAWS.

If Company terminates or suspends your account for any reason, you are prohibited from registering and creating a new account under your name, a fake or borrowed name, or the name of any third party, even if you may be acting on behalf of the third party. In addition to terminating or suspending your account, Company reserves the right to take appropriate legal action, including without limitation pursuing civil, criminal, and injunctive redress.

MODIFICATIONS

To Agreement

Company may modify this Agreement from time to time. Any and all changes to this Agreement will be posted on the Sites and revisions will be indicated by date. You agree to be bound to any changes to this Agreement when you use the Company Services after any such modification becomes effective. Company may also, in its discretion, choose to alert all users with whom it maintains email information of such modifications by means of an email to their most recently provided email address. It is therefore important that you regularly review this Agreement and keep your contact information current in your account settings to ensure you are informed of changes. You agree that you will periodically check the Sites for updates to this Agreement and you will read the messages we send you to inform you of any changes. Modifications to this Agreement shall be effective after posting.

To Services

Company reserves the right at any time to modify or discontinue, temporarily or permanently, the Company Services (or any part thereof) with or without notice. You agree that Company shall not be liable to you or to any third party for any modification, suspension or discontinuance of the Company Services.

DISPUTES

Between Users

If there is a dispute between users of the Sites, or between users and any third party, you understand and agree that Company is under no obligation to become involved. In the event that you have a dispute with one or more other users, you hereby release Company, its officers, employees, agents and successors in rights from claims, demands and damages (actual and consequential) of every kind or nature, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to such disputes and/or the Company Services.

With Company

A. Governing Law; Jurisdiction. This Agreement and all aspects of the Sites and Company Services shall be governed by and construed in accordance with the internal laws of the State of Utah, without regard to conflict of law provisions. With respect to any disputes or claims not subject to informal dispute resolution or arbitration (as set forth below), you agree not to commence or prosecute any action in connection therewith other than in the state and federal courts located in Summit County County, State of Utah, and you hereby consent to, and waive all defenses of lack of personal jurisdiction and forum non conveniens with respect to, venue and jurisdiction in such state and federal courts. Application of the United Nations Convention on Contracts for the International Sale of Goods is excluded from this Agreement. Additionally, application of the Uniform Computer Information Transaction Act (UCITA) is excluded from this Agreement. In no event shall any claim, action or proceeding by you related in any way to the Sites or Company Services be instituted more than two (2) years after the cause of action arose.

B. Informal Resolution. To expedite resolution and control the cost of any dispute, controversy or claim related to this Agreement ("Dispute"), you and Company agree to first attempt to negotiate any Dispute (except those Disputes expressly provided below) informally for at least thirty (30) days before initiating any arbitration or court proceeding. Such informal negotiations commence upon written notice from one person to the other.

C. Binding Arbitration. If you and Company are unable to resolve a Dispute through informal negotiations, either you or Company may elect to have the Dispute (except those Disputes expressly excluded below) finally and exclusively resolved by binding arbitration. Any election to arbitrate by one party shall be final and binding on the other. YOU UNDERSTAND THAT ABSENT THIS PROVISION, YOU WOULD HAVE THE RIGHT TO SUE IN COURT AND HAVE A JURY TRIAL. The arbitration shall be commenced and conducted under the Commercial Arbitration Rules of the American Arbitration Association ("AAA") and, where appropriate, the AAA’s Supplementary Procedures for Consumer Related Disputes ("AAA Consumer Rules"), both of which are available at the AAA website www.adr.org. The determination of whether a Dispute is subject to arbitration shall be governed by the Federal Arbitration Act and determined by a court rather than an arbitrator. Your arbitration fees and your share of arbitrator compensation shall be governed by the AAA Consumer Rules and, where appropriate, limited by the AAA Consumer Rules. If such costs are determined by the arbitrator to be excessive, Company will pay all arbitration fees and expenses. The arbitration may be conducted in person, through the submission of documents, by phone or online. The arbitrator will make a decision in writing, but need not provide a statement of reasons unless requested by a party. The arbitrator must follow applicable law, and any award may be challenged if the arbitrator fails to do so. Except where otherwise required by the applicable AAA rules or applicable law, the arbitration will take place in Summit County County, State of Utah. Except as otherwise provided in this Agreement, you and Company may litigate in court to compel arbitration, stay proceedings pending arbitration, or to confirm, modify, vacate or enter judgment on the award entered by the arbitrator.

D. Restrictions. You and Company agree that any arbitration shall be limited to the Dispute between Company and you individually. To the full extent permitted by law, (1) no arbitration shall be joined with any other; (2) there is no right or authority for any Dispute to be arbitrated on a class-action basis or to utilize class action procedures; and (3) there is no right or authority for any Dispute to be brought in a purported representative capacity on behalf of the general public or any other persons.

E. Exceptions to Informal Negotiations and Arbitration. You and Company agree that the following Disputes are not subject to the above provisions concerning informal negotiations and binding arbitration: (1) any Disputes seeking to enforce or protect, or concerning the validity of any of your or Company’s intellectual property rights; (2) any Dispute related to, or arising from, allegations of theft, piracy, invasion of privacy or unauthorized use; and (3) any claim for injunctive relief. If this Section is found to be illegal or unenforceable then neither you nor Company will elect to arbitrate any Dispute falling within that portion of this Section found to be illegal or unenforceable and such Dispute shall be decided by a court of competent jurisdiction within the courts listed for jurisdiction above, and you and Company agree to submit to the personal jurisdiction of that court.

CORRECTIONS

Occasionally there may be information on the Sites that contains typographical errors, inaccuracies or omissions that may relate to service descriptions, pricing, availability, and various other information. Company reserves the right to correct any errors, inaccuracies or omissions and to change or update the information at any time, without prior notice.

DISCLAIMERS

Company cannot control the nature of all of the content available on the Sites. By operating the Sites, Company does not represent or imply that Company endorses any blogs, contributions or other content available on or linked to by the Sites, including without limitation content hosted on third party websites or provided by third party applications, or that Company believes contributions, blogs or other content to be accurate, useful or non-harmful. We do not control and are not responsible for unlawful or otherwise objectionable content you may encounter on the Sites or in connection with any contributions. The Company is not responsible for the conduct, whether online or offline, of any user of the Sites or Company Services.

YOU AGREE THAT YOUR USE OF THE SITES AND COMPANY SERVICES WILL BE AT YOUR SOLE RISK. TO THE FULLEST EXTENT PERMITTED BY LAW, COMPANY, ITS OFFICERS, DIRECTORS, EMPLOYEES, AND AGENTS DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, IN CONNECTION WITH THE SITES AND THE COMPANY SERVICES AND YOUR USE THEREOF, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. COMPANY MAKES NO WARRANTIES OR REPRESENTATIONS ABOUT THE ACCURACY OR COMPLETENESS OF THE SITES CONTENT OR THE CONTENT OF ANY WEBSITES LINKED TO OUR SITES AND ASSUMES NO LIABILITY OR RESPONSIBILITY FOR ANY (A) ERRORS, MISTAKES, OR INACCURACIES OF CONTENT AND MATERIALS, (B) PERSONAL INJURY OR PROPERTY DAMAGE, OF ANY NATURE WHATSOEVER, RESULTING FROM YOUR ACCESS TO AND USE OF OUR SITES, (C) ANY UNAUTHORIZED ACCESS TO OR USE OF OUR SECURE SERVERS AND/OR ANY AND ALL PERSONAL INFORMATION AND/OR FINANCIAL INFORMATION STORED THEREIN, (D) ANY INTERRUPTION OR CESSATION OF TRANSMISSION TO OR FROM THE SITES OR COMPANY SERVICES, (E) ANY BUGS, VIRUSES, TROJAN HORSES, OR THE LIKE WHICH MAY BE TRANSMITTED TO OR THROUGH OUR SITES BY ANY THIRD PARTY, AND/OR (F) ANY ERRORS OR OMISSIONS IN ANY CONTENT AND MATERIALS OR FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF ANY CONTENT POSTED, TRANSMITTED, OR OTHERWISE MADE AVAILABLE VIA THE SITES. COMPANY DOES NOT WARRANT, ENDORSE, GUARANTEE, OR ASSUME RESPONSIBILITY FOR ANY PRODUCT OR SERVICE ADVERTISED OR OFFERED BY A THIRD PARTY THROUGH THE SITES OR ANY HYPERLINKED SITES OR FEATURED IN ANY BANNER OR OTHER ADVERTISING, AND COMPANY WILL NOT BE A PARTY TO OR IN ANY WAY BE RESPONSIBLE FOR MONITORING ANY TRANSACTION BETWEEN YOU AND THIRD-PARTY PROVIDERS OF PRODUCTS OR SERVICES. AS WITH THE PURCHASE OF A PRODUCT OR SERVICE THROUGH ANY MEDIUM OR IN ANY ENVIRONMENT, YOU SHOULD USE YOUR BEST JUDGMENT AND EXERCISE CAUTION WHERE APPROPRIATE.

LIMITATIONS OF LIABILITY

IN NO EVENT SHALL COMPANY OR ITS DIRECTORS, EMPLOYEES, OR AGENTS BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, EXEMPLARY, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES, INCLUDING LOST PROFIT, LOST REVENUE, LOSS OF DATA OR OTHER DAMAGES ARISING FROM YOUR USE OF THE SITES OR COMPANY SERVICES, EVEN IF COMPANY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, COMPANY’S LIABILITY TO YOU FOR ANY CAUSE WHATSOEVER AND REGARDLESS OF THE FORM OF THE ACTION, WILL AT ALL TIMES BE LIMITED TO THE AMOUNT PAID, IF ANY, BY YOU TO COMPANY FOR THE COMPANY SERVICES DURING THE PERIOD OF ONE (1) MONTH PRIOR TO ANY CAUSE OF ACTION ARISING.

CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MAY HAVE ADDITIONAL RIGHTS.

IF YOU ARE A CALIFORNIA RESIDENT, YOU WAIVE CALIFORNIA CIVIL CODE SECTION 1542, WHICH SAYS: "A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR."

INDEMNITY

You agree to defend, indemnify and hold Company, its subsidiaries, and affiliates, and their respective officers, agents, partners and employees, harmless from and against, any loss, damage, liability, claim, or demand, including reasonable attorneys’ fees and expenses, made by any third party due to or arising out of your contributed content, use of the Company Services, and/or arising from a breach of this Agreement and/or any breach of your representations and warranties set forth above. Notwithstanding the foregoing, Company reserves the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify Company, and you agree to cooperate, at your expense, with Company’s defense of such claims. Company will use reasonable efforts to notify you of any such claim, action, or proceeding which is subject to this indemnification upon becoming aware of it.

NOTICES

Except as explicitly stated otherwise, any notices given to Company shall be given by email to the address listed in the contact information below. Any notices given to you shall be given to the email address you provided during the registration process, or such other address as each party may specify. Notice shall be deemed to be given twenty-four (24) hours after the email is sent, unless the sending party is notified that the email address is invalid. We may also choose to send notices by regular mail.

USER DATA

Our Sites will maintain certain data that you transfer to the Sites for the purpose of the performance of the Company Services, as well as data relating to your use of the Company Services. Although we perform regular routine backups of data, you are primarily responsible for all data that you have transferred or that relates to any activity you have undertaken using the Company Services. You agree that Company shall have no liability to you for any loss or corruption of any such data, and you hereby waive any right of action against Company arising from any such loss or corruption of such data.

ELECTRONIC CONTRACTING

Your use of the Company Services includes the ability to enter into agreements and/or to make transactions electronically. YOU ACKNOWLEDGE THAT YOUR ELECTRONIC SUBMISSIONS CONSTITUTE YOUR AGREEMENT AND INTENT TO BE BOUND BY AND TO PAY FOR SUCH AGREEMENTS AND TRANSACTIONS. YOUR AGREEMENT AND INTENT TO BE BOUND BY ELECTRONIC SUBMISSIONS APPLIES TO ALL RECORDS RELATING TO ALL TRANSACTIONS YOU ENTER INTO RELATING TO THE COMPANY SERVICES, INCLUDING NOTICES OF CANCELLATION, POLICIES, CONTRACTS, AND APPLICATIONS. In order to access and retain your electronic records, you may be required to have certain hardware and software, which are your sole responsibility.

MISCELLANEOUS

This Agreement constitutes the entire agreement between you and Company regarding the use of the Company Services. The failure of Company to exercise or enforce any right or provision of this Agreement shall not operate as a waiver of such right or provision. The section titles in this Agreement are for convenience only and have no legal or contractual effect. This Agreement operates to the fullest extent permissible by law. This Agreement and your account may not be assigned by you without our express written consent. Company may assign any or all of its rights and obligations to others at any time. Company shall not be responsible or liable for any loss, damage, delay or failure to act caused by any cause beyond Company's reasonable control. If any provision or part of a provision of this Agreement is unlawful, void or unenforceable, that provision or part of the provision is deemed severable from this Agreement and does not affect the validity and enforceability of any remaining provisions. There is no joint venture, partnership, employment or agency relationship created between you and Company as a result of this Agreement or use of the Sites and Company Services. Upon Company’s request, you will furnish Company any documentation, substantiation or releases necessary to verify your compliance with this Agreement. You agree that this Agreement will not be construed against Company by virtue of having drafted them. You hereby waive any and all defenses you may have based on the electronic form of this Agreement and the lack of signing by the parties hereto to execute this Agreement.

CONTACT US

In order to resolve a complaint regarding the Company Services or to receive further information regarding use of the Company Services, please contact Company as set forth below or, if any complaint with us is not satisfactorily resolved, and you are a California resident, you can contact the Complaint Assistance Unit of the Division of Consumer Services of the Department of Consumer Affairs in writing at 400 "R" Street, Sacramento, California 95814 or by telephone at 1-916-445-1254.

MedTech Genie LLC

1086 Old Stone House Way

Park City, UT 84098

Email: [email protected]

Phone: (801) 657-9803

This page intentionally left blank.

GENERAL INSTRUCTIONS
WHAT IS A TERMS OF USE AGREEMENT?
A Terms of Use Agreement is a written set of rules and regulations between two parties, the User and the Company, that the User must agree to follow in order to use the Company’s website and services.
WHEN IS A TERMS OF USE AGREEMENT NEEDED?
While Terms and Conditions are not required by law, any website, especially e-commerce or social networking websites or applications and any website or internet service provider that stores a User’s personal data, should consider having Terms and Conditions.
A written set of Terms and Conditions protects the Company and acts an instruction manual for its website. It allows the Company to explain things related to its service or product, including, among other things:
•  how purchases, payment, and returns are handled• ownership and use of content and intellectual property• how Users must conduct themselves, including any prohibited behavior•  limitations on liability and disclaimers•  the Company’s privacy policy
WHO NEEDS A TERMS OF USE AGREEMENT?
Almost every website or application that provides a service or product has a Terms of Use Agreement.
Here are some examples of websites and apps that use a Terms of Use Agreement:
•  E-Commerce Company - Ebay, Amazon, Target, Gap•  Social Media Website or Application - Facebook, Instagram, Twitter, Snapchat
 •  Search Engine - Google, Yahoo, Bing•  Website or ApplicationProviding a Service or Product -YouTube, Apple, Uber•  Gaming Website or Application - Playstation, Pokemon Go, Candy Crush
WHAT SHOULD BE INCLUDED IN A TERMS OF USE?
A simple Terms of Service should generally have at least the following:
•  Who is the Company providing the service or product•  What is the service or product provided by the Company•  Where is the Company’s website•  When will the agreement terminate•  Why might the User not be granted access to the website•  How does the User agree to accept the Terms of Service
The Company can tailor the rules and regulations, or “terms of use”, according to the service or product it provides and its specific needs. The Terms of Use Agreement can be posted on the Company’s website either as a browsewrap agreement or a clickwrap agreement.
OTHER NAMES 
As a reference, a Terms of Use Agreement is known by other names:
•  Terms of Service Agreement•  Terms and Conditions•  User Agreement•  Statement of Rights and Responsibilities•  Disclaimer•  TOU•  ToS•  TOS•  TOC

magnifier linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram